What this means
Researchers plan to track adults aged 60 or older with IBD who start a new advanced treatment. They want to see whether immune aging and frailty signs predict good or bad results. This study has not started yet, so it cannot tell us anything about the answer.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 60 and over
- Where
- Not listed
The science
- Registered title
- Immune Aging and Advanced Therapy Outcomes in Older Adults With IBD
- Trial ID
- NCT07828886 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Frailty, Immunosenescence
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Ages
- 60 Years to no maximum
- Dates
- First posted Sep 18, 2026 · updated Oct 13, 2026
Registry summary
The goal of this observational study is to learn whether signs of immune aging and frailty can help predict the balance of benefits and risks of advanced therapies in adults aged 60 years or older with inflammatory bowel disease (IBD) who are starting a new advanced therapy. Treatment will be chosen by the participant's usual clinical team and will not be assigned by the study.
The main questions it aims to answer are:
Are baseline immune-aging and frailty characteristics associated with net clinical benefit at 52 weeks, defined as steroid-free clinical remission without serious infection, treatment discontinuation because of adverse events, IBD-related hospitalization, or IBD-related surgery? Can a low-cost combination of clinical and laboratory markers help identify older adults with IBD who are more likely to have favorable or unfavorable outcomes after starting advanced therapy?
Participants will:
Continue the advanced therapy selected as part of their usual clinical care. Complete study assessments of frailty, nutritional status, disease activity, and other health factors.
Have routine and study-related blood tests, including measures related to immune aging such as CD4/CD8 ratio and interleukin-6 (IL-6).
Be followed at approximately baseline, weeks 6, 14, 26, and 52, with longer-term safety follow-up planned to week 104 when feasible.
Have information collected on remission, infections, hospitalizations, surgery, treatment continuation or change, and other health outcomes.